Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC

In our exclusive interview, Borghaei and Gunuganti discussed patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike